Merger

A $2.4B tech acquisition seems distant from healthcare, but Qualcomm's move to buy Alphawave is building the essential AI infrastructure for medicine's future.

A 1.26% stake in Just Group, held via derivatives by Balyasny, reveals a classic merger arbitrage strategy as Brookfield's £2.4bn acquisition nears.

A former oil driller pivots to advanced recycling, but can its plastics-to-fuel plant navigate financial risks and environmental scrutiny in Texas?

A mandatory disclosure from a Boston investment giant reveals its position in a $1.4B merger. What does it signal for the future of the auto industry?

A deep dive into the valuation impasse that scuttled a major oil merger, and what the fallout means for Parex, GeoPark, and Latin American energy M&A.

SRN Advisors is consolidating its dividend ETFs, shifting from a defensive strategy to pure growth and highlighting a major consolidation trend in finance.

An unsolicited bid from Paramount Skydance challenges Netflix's deal for WBD, sparking a high-stakes war for Hollywood's most iconic content library.

A hedge fund's subtle move in Unite Group offers a rare glimpse into the high-stakes strategy behind the UK's student housing consolidation boom.

Arkansas-based Home BancShares is buying its way into Tennessee's booming economy. We dissect the 'triple accretive' deal to acquire Mountain Commerce.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

TotalEnergies is creating the UK's largest independent oil producer. A bold bet on fossil fuel efficiency or a contradiction to its green energy goals?

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

Hedge fund Balyasny Asset Management reveals a major stake in the Unite-Empiric takeover, signaling a high-stakes arbitrage play amid regulatory scrutiny.

A shareholder lawsuit challenges Comerica's $10.9B sale to Fifth Third, citing a rushed process, CEO self-interest, and an undervalued price.

A PE firm's operational overhaul of a corporate carve-out leads to a strategic sale, highlighting the consolidation and tech trends reshaping security.

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.

The medtech giant projects robust growth with an ambitious pipeline, but a high-stakes regulatory showdown over a key acquisition could redefine its future.